<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04035902</url>
  </required_header>
  <id_info>
    <org_study_id>KUH 2019-05-008</org_study_id>
    <nct_id>NCT04035902</nct_id>
  </id_info>
  <brief_title>Intraoperative IV Iron on Postoperative Red Blood Cell Recovery</brief_title>
  <official_title>Intraoperative IV Iron on the Postoperative Recovery of Red Blood Cell in Hip Arthroplasty Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Konkuk University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Konkuk University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the present study is to determine the impact of intraoperative IV-iron
      supplementation on postoperative recovery of RBC mass by retrospectively analyzing and
      comparing the changes of postoperative hematocrit values after the surgery in patients
      underwent elective uni-limb total knee arthroplasty surgery with or without IV-iron
      supplementation during surgery
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative hematocrit (%)</measure>
    <time_frame>7 days after surgery</time_frame>
    <description>hematocrit is evaluated on postoperative 7 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>volume of post-operative bleeding (ml)</measure>
    <time_frame>7 day</time_frame>
    <description>total volume of postoperative bleeding collected in the drainage container (hemovac)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intraoperative blood transfusion (ml)</measure>
    <time_frame>1 day</time_frame>
    <description>total volume of intraoperative blood transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post-operative blood transfusion (ml)</measure>
    <time_frame>7 days</time_frame>
    <description>total amount of post-operative blood transfusion (ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post-operative serum ferritin level (ng/ml)</measure>
    <time_frame>1 day</time_frame>
    <description>post-operative serum ferritin level (ng/ml) is checked immediately after surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Osteoarthritis, Hip</condition>
  <arm_group>
    <arm_group_label>ferric carboxymaltose 1000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ferric carboxymaltose is administered during surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ferric carboxymaltose is not administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric carboxymaltose</intervention_name>
    <description>Ferric carboxymaltose is administered during surgery</description>
    <arm_group_label>ferric carboxymaltose 1000 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>control</intervention_name>
    <description>Ferric carboxymaltose is not administered</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Patients with osteoarthritis in knee joint undergoing elective uni-limb total knee
             arthroplasty surgery

          -  Patients provided a written informed consent.

          -  Patients with s-ferritin &lt; 300 mg/dl (male) or 200 mg/dl (female)

          -  Patients with preoperative serum hemoglobin concentration &gt;10 g/dL

        Exclusion criteria

          -  Patients with history of anaphylaxis, iron overload, active infection.

          -  Patients received or receiving intraoperative and preoperative blood salvaged,
             allogenic blood transfusion, recombinant human erythropoietin, or undergoing acute
             normovolemic hemodilution.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tae-Yop Kim, MD PhD</last_name>
    <phone>0220305445</phone>
    <email>taeyop@gmail.com</email>
  </overall_contact>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 21, 2019</study_first_submitted>
  <study_first_submitted_qc>July 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <last_update_submitted>November 4, 2019</last_update_submitted>
  <last_update_submitted_qc>November 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Konkuk University Medical Center</investigator_affiliation>
    <investigator_full_name>Tae-Yop Kim, MD PhD</investigator_full_name>
    <investigator_title>Professor Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>iron</keyword>
  <keyword>arthroplasty</keyword>
  <keyword>red blood cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

